Physician profile
Shereen Khalid
NPI 1902478597
$689.74
in general payments reported to CMS, 2019-2025
15 companies · $15.16 in 2025
The $15.16 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $65.85 · 2022: $389 · 2023: $202 · 2024: $17.04 · 2025: $15.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $234.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $138.13 | 2022-2023 | |
| Novo Nordisk INC | $136.63 | 2021-2023 | Ozempic |
| Lilly USA, LLC | $86.96 | 2022-2023 | Mounjaro |
| Amgen INC. | $77.49 | 2021-2022 | |
| Almatica Pharma LLC | $39.81 | 2023 | Loreev Xr |
| Exact Sciences Corporation | $37.73 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $34.83 | 2022-2023 | |
| Mylan Specialty L.P. | $24.70 | 2022 | |
| Nestle Healthcare Nutrition INC. | $21.57 | 2021 | |
| Grt US Holding, INC. | $20.64 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.86 | 2022 | |
| Array Biopharma INC | $15.16 | 2025 | Lorbrena, Braftovi, Mektovi |
| Idorsia Pharmaceuticals US INC | $14.02 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals Lp | $13.44 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shereen Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.